Skip to main content

Table 4 Risk factor analysis for venous thromboembolism (VTE) occurrence within 1 year after lung cancer diagnosis

From: Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study

  UnivariateMultivariate**
  sHR (95% CI)p-valuesHR (95% CI)p-value
Age<  55
55–650.89 (0.61–1.28)0.5190.94 (0.64–1.38)0.758
65–750.66 (0.45–0.99)0.0420.78 (0.52–1.17)0.232
≥ 750.42 (0.27–0.65)0.00010.65 (0.41–1.04)0.071
GenderMale
Female1.07 (0.80–1.43)0.6501.10 (0.82–1.48)0.523
Metastasis2.86 (2.12–3.86)< 0.00011.83 (1.30–2.58)0.0005
VTE concomitant with cancer diagnosis*4.26 (1.67–10.88)0.0034.07 (1.57–10.52)0.004
Lung cancer surgery0.96 (0.64–1.44)0.955  
Other surgery2.05 (1.48–2.82)< 0.00011.49 (1.06–2.09)0.022
Chemotherapy4.63 (3.45–6.23)< 0.00013.44 (2.44–4.85)< 0.0001
Bevacizumab2.39 (1.29–4.42)0.006  
Oral targeted therapy1.19 (0.56–2.54)0.655  
Radiotherapy1.95 (1.41–2.71)< 0.0001  
Blood transfusion1.91 (1.16–3.15)0.012  
Non-surgical hospitalization1.53 (1.16–2.03)0.003  
  1. *Risk of recurrent VTE beyond 6 months after the first VTE
  2. **Multivariate analysis adjusted for age and gender